Answer
The terminal half-life of antibody-conjugated MMAE at Cycle 6 of polatuzumab vedotin treatment is approximately 12 days (95% CI: 8.1–19.5 days).
Sources for this answer
- Polivy 30 mg and 140 mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 9Document updated
Sources checked